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The Biological Basis of Hutchinson-Gilford
Syndrome (HGS): Relationship to
Mutagens in the Lamin A/C Gene (LMNA)
and to Other Known Laminopathies
This PA is a new initiative to support research
to understand how mutations in the gene for
lamin A/C affect nuclear structure, thus lead-
ing to bothdysfunction of the nuclear enve-
lope, and depending on the mutation,
Hutchinson-Gilford syndrome in humans
(Eriksson et al., manuscript in preparation).
Lamins A and C are coded by a single devel-
opmentally regulated gene designated
LMNA; lamin C is a splice variant and lacks
the carboxyl terminus present in lamin A. At
least 6 other rare human disorders due to
lamin A/C mutations (known collectively as
laminopathies) besides HGS have been
described so far: Emery–Dreifuss muscular
dystrophy (Bonne et al., 1999), dilated car-
diomyopathy (Fatkin et al., 1999), familial
partial lipodystrophy (Shackleton et al.,
2000), limb girdle muscular dystrophy
(Muchir et al., 2000), Charcot Marie-Tooth
disorder type 2 (De Sandre-Giovanni et al.,
2002), and mandibuloacral dysplasia (Novelli
et al., 2002). These disorders and their rela-
tionship to LMNA mutations have been
reviewed recently {Burke and Stewart
(2002)}, and Hutchinson (2002) has
reviewed the function of lamins in the
nuclear envelope.
This PA will use the National Institutes
of Health (NIH) research project grant R01
award mechanism. As an applicant, you will
be solely responsible for planning, directing,
and executing the proposed project. Contact
the program staff listed under “inquiries” for
further information. This PA uses just-in-
time concepts. It also uses the modular as well
as the non-modular budgeting formats (see
http://grants.nih.gov/grants/funding/modular/
modular.htm). Specifically, if you are submit-
ting an application with direct costs in each
year of $250,000 or less, use the modular for-
mat. Otherwise follow the instructions for
non-modular research grant applications. 
This program does not require cost shar-
ing as defined in the current NIH Grants
Policy statement at http://grants.nih.gov/
grants/policy/nihgs_2001/part_i_1.htm.
Applications must be prepared using the
PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). The PHS
398 is available at http://grants.nih.gov/
grants/funding/phs398/phs398.html in an
interactive format. For further assistance
contact Grants Info, 301-435-0714, e-mail:
GrantsInfo@nih.gov.
Applications submitted in response to
this PA will be accepted at the standard
application deadlines, which are available at
http://grants.nih.gov/grants/dates.htm.
Application deadlines are also indicated in
the PHS 398 application kit.
Applications must be received by or
mailed before the receipt dates described at
http://grants.nih.gov/grants/funding/sub-
missionschedule.htm. The CSR will not
accept any application in response to this
PA that is essentially the same as one cur-
rently pending initial review unless the
applicant withdraws the pending applica-
tion. The CSR will not accept any applica-
tion that is essentially the same as one
already reviewed. This does not preclude
the submission of a substantial revision of
an application already reviewed, but such
application must include an Introduction
addressing the previous critique.
Contact: Felipe Sierra, Biology of Aging
Program, National Institute of Aging,
Gateway Building, Room 2C231, Bethesda,
MD 20892-9525 USA, 301-496-6402, fax:
301-402-0010, e-mail: sierraf@nia.nih.gov;
Dr. Stephen Goldman, Vascular Biology
Research Program, Division of Heart and
Vascular Disease, National Heart, Lung and
Blood Institute, Bethesda, MD 20892-7956,
USA, Carrier Zip 20814, 301-435-0560, fax:
301-480-2858, e-mail: goldmans@nhlbi.
nih.gov. Reference: PA No. PA-03-069.
Individual Biomedical Informatics
Fellowships
Individual biomedical informatics fellowships
provide support for the training of informat-
ics scientists able to perform research into
basic informatics problems or to application
of informatics to any area of biomedicine,
including clinical medicine, basic biomedical
research, clinical and health services research,
public health, professional education, and
administration. Post-doctoral, pre-doctoral
and, in certain specified fields, some post-bac-
calaureate candidates are eligible.
Individuals must submit the application
form PHS Individual National Research
Service Award (PHS 416-1, rev. 12/98).
Applications must include at least three
sealed letters of reference. applications with-
out at least three letters of reference may be
returned or delayed in review.
Application kits are available at most
institutional offices of sponsored research
offices, and online at http://grants.nih.gov/
grants/funding/416/ phs416.htm
Complete Item 3 on the face page of the
application indicating that the application is
in response to this announcement and print
F37 National Library of Medicine (NLM)
Individual Informatics Fellowship.
If the applicant has been lawfully admit-
ted to the United States for permanent resi-
dence, the appropriate item should be
checked on the Face Page of the application.
Applicants who have applied for and have
not yet been granted admission as a perma-
nent resident should check the Permanent
Resident block on the Face Page of the PHS
416-1 application, and also write in the
word “pending.” A notarized statement doc-
umenting legal admission for permanent res-
idence must be submitted prior to the
issuance of an award. 
Submit a signed, typewritten original of
the application (including the Checklist,
Personal Data form, at least three sealed ref-
erence letters, and all other required materi-
als) and two (2) exact, clear, single-sided
photocopies of the signed application, in
one package to Center for Scientific Review,
NIH, 6701 Rockledge Dr., Room 1040,
MSC 7710, Bethesda, MD 20892-7710
USA, Bethesda, MD 20817 USA (for
express/courier service)
Incomplete applications will not be
reviewed.
An individual may not have more than
one individual NRSA fellowship or compa-
rable application pending review or award at
the NIH or other Department of Health
and Human Services agencies at the same
time. The CSR will not accept any applica-
tion in response to this PA that is essentially
the same as one currently pending initial
review unless the applicant withdraws the
pending application. The CSR will not
accept any application that is essentially the
same as one already reviewed. This does not
preclude the submission of a substantial
revision of an application already reviewed,
but such application must include an intro-
duction addressing the previous critique.
Fellowship applications undergo a
review process that takes between 5 and 8
months. The receipt dates and the three
annual review cycles are as follows: applica-
tion receipt dates—5 April, 5 August, 5
December; initial review dates—June/July,
October/November, February/March; sec-
ondary review dates—August/September,
December/January,  April/May; range of
likely start dates—1 September–1 December,
1 January–1 March, 1 May–1 July. 
From time to time, the NLM may
change some elements of this announce-
ment. Please consider the version on the
NLM website at http://www.nlm.nih.gov/
to view the most recent revision.
Contact: Carol A. Bean, Extramural
Programs, NLM, Rockledge 1, Suite 301,
6705 Rockledge Dr., Bethesda, MD 20892-
9525 USA, 301-594-4882, fax: 301-402-
2952; Merlyn M. Rodrigues, Extramural
Programs, NLM, Rockledge 1, Suite 301,
6705 Rockledge Dr., Bethesda, MD 20892-
9525 USA, 301-594-4253, fax: 301-402-
2952. Reference: PA No. PAR-03-070
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Advances in Polycystic Kidney Disease
The National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDKD)
through its Division of Kidney, Urologic
and Hematologic Diseases (DKUHD)
invites experienced and new investigators to
submit research grant applications to pursue
basic and applied investigations in order to
better understand the etiology and patho-
genesis of polycystic kidney disease (PKD),
in both its autosomal dominant and autoso-
mal recessive forms. Such applications may
examine the genetic determinants, and cel-
lular and molecular mechanisms, which dis-
rupt normal kidney function; mechanisms
of cyst formation and growth; development
of experimental model systems; develop-
ment of markers of disease progression; and
the identification of innovative therapeutic
interventions and gene targeted strategies to
prevent progressive renal insufficiency due
to this disorder. The intent of this PA is to
intensify investigator-initiated research, to
attract new investigators to the field, and to
increase interdisciplinary research. The ulti-
mate aim is to facilitate PKD-related
research studies, which will provide the
basis for new therapeutic approaches.
This PA will use the NIH R01 and R21
award mechanism(s). Applications must be
prepared using the PHS 398 research grant
application instructions and forms (rev.
5/2001). The PHS 398 is available at
http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For
further assistance contact Grants Info, 301-
435-0714, e-mail: GrantsInfo@nih.gov.
Applications submitted in response to
this PA will be accepted at the standard
application deadlines, which are available at
http://grants.nih.gov/grants/dates.htm.
Application deadlines are also indicated in
the PHS 398 application kit.
Applications must be mailed on or
before the receipt dates described at
http://grants.nih.gov/grants/funding/
submissionschedule.htm. The CSR will not
accept any application in response to this
PA that is essentially the same as one cur-
rently pending initial review unless the
applicant withdraws the pending applica-
tion. The CSR will not accept any applica-
tion that is essentially the same as one
already reviewed. This does not preclude
the submission of a substantial revision of
an application already reviewed, but such
application must include an Introduction
addressing the previous critique. 
Contact: Catherine M. Meyers, Program
Director of Inflammatory Kidney Diseases,
Division of Kidney, Urologic and
Hematologic Diseases, NIDDKD, 6707
Democracy Blvd., Room 641, Bethesda,
MD 20892-5458 USA, 301-594-7717, fax:
301-480-3510, e-mail: cm420i@nih.gov.
Reference: PA No. 03-073
Technology Development for Biomedical
Applications
This PA replaces PAR-02-091.
The purpose of this PA is to invite innov-
ative applications for 1) the development of
new and improved instruments or devices,
2) the development of new methodologies
using existing instruments, or 3) the develop-
ment of software related to instrumentation.
Any of these projects should propose tools,
methodologies, or software that can be used
by a wide range of biomedical or clinical
researchers; projects that focus on specific
organs or diseases are not responsive to this
announcement. Awards made for applications
received in response to this announcement
will employ the R21 and the R21/R33 mech-
anisms that are designed to support high-risk
applications for which few if any preliminary
findings are available. Investigators with sub-
stantial preliminary data should seek an R01
grant by submitting an unsolicited applica-
tion at the standard receipt date or by
responding to a particular PA.
Questions about the suitability of propos-
als should be addressed to program staff listed
in the “Where to Send Inquiries” section well
before submission. Proposals that are focused
on a specific organ or disease will be returned
without review; however, proposals may use a
specific organ or disease as a model system.
Investigators may also want to look at the




becon_funding.htm) web pages for funding
opportunities in bioengineering research or
biomedical imaging research. 
This PA is similar in spirit to the
Instrument Development for Biological
Research program in the Directorate for
Biological Sciences at the National Science
Foundation (NSF) (http://www.nsf.gov/cgi-
bin/getpub?nsf98119). The major difference
between the two programs is that instru-
mentation for the conduct of disease-orient-
ed research is specifically excluded from the
NSF program, although some instrument
development proposals could be considered
either under this PA or by NSF. Applicants
are encouraged to contact program staff at
either NSF or NIH to discuss which pro-
gram is more appropriate. 
This PA will use the NIH R21 and
R21/R33 award mechanism(s). As an appli-
cant, you will be solely responsible for plan-
ning, directing, and executing the proposed
project.
Specific features of this mechanism
include: 1) single submission and evaluation
of both a feasibility/pilot phase (R21) and
an expanded development phase (R33) as
one application, 2) expedited transition of
the R21 feasibility phase to a R33 develop-
ment phase for combined applications,
3) flexible budgets, and 4) flexible staging of
feasibility and development phases.
Applications under this PA will use
either the combined R21/R33 mechanism
or the R21 mechanism alone. Applications
using just the R33 mechanism will not be
considered. An application using the R21
mechanism alone is appropriate when the
possible outcomes of the proposed research
are unclear; under these conditions, it would
not be possible to propose quantitative mile-
stones or describe the R33 phase of the
research. Applicants are strongly encouraged
to contact program staff with any questions
about the appropriate mechanism. Refer to
the “Where to Send Inquiries” section of
this PA for program staff contacts.
Applications must be prepared using the
PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). The PHS
398 is available at http://grants.nih.gov/
grants/funding/phs398/phs39.html in an
interactive format. For further assistance
contact Grants Info, 301-435-0714, e-mail:
GrantsInfo@nih.gov.
Applications submitted in response to
this PA will be accepted on 1 June and
1 October annually. Both new applications
and revisions to previously reviewed applica-
tions are due on the same date.
The CSR will not accept any application
in response to this PA that is essentially the
same as one currently pending initial review
unless the applicant withdraws the pending
application. The CSR will not accept any
application that is essentially the same as one
already reviewed. This does not preclude the
submission of a substantial revision of an
application already reviewed, but such appli-
cation must include an Introduction
addressing the previous critique. Instructions
for preparing a revised application can be
found at http://grants.nih.gov/grants/
funding/phs398/section_1.html#8_research.
Contact: Gregory K. Farber, Division of
Biomedical Technology, National Center
for Research Resources, 6701 Democracy
Blvd., MSC 4874, Bethesda, MD 20892-
4874 USA, 301-435-0755, fax: 301-480-
3659, e-mail: gf48a@nih.gov; Bo Hong,
Office of Review, NCRR, 6701 Democracy
Blvd., MSC 4874, Bethesda, MD 20892-
4874 USA, 301-435-0813, fax: 301-480-
3660, e-mail: mv10f@nih.gov. Reference:
PA No. PAR-03-075
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